Traws Pharma Inc
TRAW1.560USD
+0.100+6.85%
取引時間 （ET）15分遅れの株価
7.92M時価総額
損失額直近12ヶ月PER
詳細情報 Traws Pharma Inc 企業名
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
企業情報
企業コードTRAW
会社名Traws Pharma Inc
上場日Jul 25, 2013
最高経営責任者「CEO」Dr. Iain D. Dukes, Ph.D.
従業員数7
証券種類Ordinary Share
決算期末Jul 25
本社所在地12 Penns Trail
都市NEWTOWN
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号18940
電話番号12677593680
ウェブサイトhttps://www.onconova.com/
企業コードTRAW
上場日Jul 25, 2013
最高経営責任者「CEO」Dr. Iain D. Dukes, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Nikolay Savchuk, Ph.D.
Dr. Nikolay Savchuk, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
251.90K
+202.70%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Interim Chief Executive Officer, Company Secretary, Director
Interim Chief Executive Officer, Company Secretary, Director
81.19K
-2.44%
Mr. Jack E. Stover, CPA
Mr. Jack E. Stover, CPA
Independent Chairman of the Board
Independent Chairman of the Board
8.00
-11.11%
Dr. C. David Pauza, Ph.D.
Dr. C. David Pauza, Ph.D.
Chief Scientific Officer, Virology
Chief Scientific Officer, Virology
--
--
Dr. Robert Redfield, M.D.
Dr. Robert Redfield, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles Parker
Mr. Charles Parker
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. M. Teresa Shoemaker
Ms. M. Teresa Shoemaker
Independent Director
Independent Director
--
--
Dr. Werner Cautreels
Dr. Werner Cautreels
Director
Director
--
--
Dr. Trafford Clarke, Ph.D.
Dr. Trafford Clarke, Ph.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Nikolay Savchuk, Ph.D.
Dr. Nikolay Savchuk, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
251.90K
+202.70%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Interim Chief Executive Officer, Company Secretary, Director
Interim Chief Executive Officer, Company Secretary, Director
81.19K
-2.44%
Mr. Jack E. Stover, CPA
Mr. Jack E. Stover, CPA
Independent Chairman of the Board
Independent Chairman of the Board
8.00
-11.11%
Dr. C. David Pauza, Ph.D.
Dr. C. David Pauza, Ph.D.
Chief Scientific Officer, Virology
Chief Scientific Officer, Virology
--
--
Dr. Robert Redfield, M.D.
Dr. Robert Redfield, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles Parker
Mr. Charles Parker
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Symbio
57.00K
0.00%
地域別USD
会社名
収益
比率
United States
57.00K
100.00%
事業別
地域別
事業別USD
会社名
収益
比率
Symbio
57.00K
0.00%
株主
更新時刻: Sat, May 17
更新時刻: Sat, May 17
株主統計
種類
株主統計
株主統計
比率
Viriom Inc
10.88%
OrbiMed Advisors, LLC
10.88%
Perceptive Advisors LLC
7.58%
Adage Capital Management, L.P.
5.93%
Savchuk (Nikolay)
4.53%
Other
60.20%
株主統計
株主統計
比率
Viriom Inc
10.88%
OrbiMed Advisors, LLC
10.88%
Perceptive Advisors LLC
7.58%
Adage Capital Management, L.P.
5.93%
Savchuk (Nikolay)
4.53%
Other
60.20%
種類
株主統計
比率
Private Equity
18.46%
Corporation
10.88%
Individual Investor
7.84%
Hedge Fund
7.63%
Investment Advisor/Hedge Fund
4.58%
Investment Advisor
0.53%
Research Firm
0.02%
Other
50.05%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
57
2.78M
49.95%
+103.15K
2025Q1
59
3.22M
71.94%
+1.74M
2024Q4
58
1.47M
44.66%
+775.47K
2024Q3
57
942.34K
34.05%
+834.58K
2024Q2
58
213.81K
16.43%
+135.65K
2024Q1
55
74.05K
8.78%
-3.08K
2023Q4
60
70.75K
8.42%
-22.28K
2023Q3
70
76.41K
9.11%
-47.84K
2023Q2
73
78.91K
9.41%
-30.66K
2023Q1
104
61.55K
7.34%
-62.19K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Viriom Inc
605.53K
10.88%
--
--
Apr 28, 2025
OrbiMed Advisors, LLC
605.53K
10.88%
--
--
Mar 31, 2025
Perceptive Advisors LLC
421.78K
7.58%
+257.62K
+156.94%
Mar 31, 2025
Adage Capital Management, L.P.
330.00K
5.93%
+330.00K
--
Mar 31, 2025
Savchuk (Nikolay)
251.90K
4.53%
+168.68K
+202.70%
Apr 28, 2025
Vestal Point Capital, LP
175.00K
3.15%
+100.00K
+133.33%
Mar 31, 2025
Cautreels (Werner C)
98.35K
1.77%
-6.00K
-5.75%
Apr 28, 2025
Dukes (Iain D)
81.19K
1.46%
-2.03K
-2.44%
Apr 28, 2025
Alyeska Investment Group, L.P.
52.63K
0.95%
-64.08K
-54.91%
Mar 31, 2025
Geode Capital Management, L.L.C.
33.38K
0.6%
+12.58K
+60.47%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Sep 17, 2024
Merger
25<1
Sep 17, 2024
Merger
25<1
Sep 17, 2024
Merger
25<1
Sep 17, 2024
Merger
25<1
May 20, 2021
Merger
15<1
May 20, 2021
Merger
15<1
日付
種類
比率
Sep 17, 2024
Merger
25<1
Sep 17, 2024
Merger
25<1
Sep 17, 2024
Merger
25<1
Sep 17, 2024
Merger
25<1
May 20, 2021
Merger
15<1
May 20, 2021
Merger
15<1
May 20, 2021
Merger
15<1
May 20, 2021
Merger
15<1
